NSE · LASA · Pharmaceuticals
Lasa Supergenerics Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹147 Cr with net profit ₹-15 Cr — a -10.01% net margin, versus -20.81% the period before.
Shareholding
As of 2026-03-31
- Promoter53.65%
- Public46.35%
27,702 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.48× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #83 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,77,444 Cr | 176.1 | 5.71 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,19,101 Cr | 214.6 | 3.46 | 11.27% | 14% |
| Zydus Lifesciences Ltd. | ₹1,11,990 Cr | 88.75 | 4.13 | 18.59% | 18.86% |
| Lupin Limited | ₹1,11,885 Cr | 19.67 | 4.98 | 23.76% | 19.4% |
| Mankind Pharma Limited | ₹1,07,077 Cr | 192.91 | 6.57 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,246 Cr | 88.01 | 18.16 | 16.77% | 15.04% |
| Dr Reddys Laboratories Ltd. | ₹95,344 Cr | 431.06 | 2.52 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹92,388 Cr | 100.3 | 2.44 | 9.25% | 10.5% |
| Biocon Ltd. | ₹69,837 Cr | 545.38 | 2.05 | 1.14% | 2.3% |
| Alkem Laboratories Ltd. | ₹67,823 Cr | 286.92 | 4.91 | 16.66% | 15.65% |
| Lasa Supergenerics Ltd.(this company) | ₹36 Cr | — | 0.72 | -26.3% | -135.56% |
AI analysis
AI-generated · google/gemini-2.5-flashLasa Supergenerics Ltd. operates with a market capitalization of Rs 36 Cr. The company reported a revenue of Rs 147.46 Cr and a negative profit margin of -135.56%. For the year ending March 2025, the earnings per share (EPS) was -2.95.
Positives
- +The debt-to-equity ratio is 0.13, indicating a relatively low reliance on debt financing.
- +The number of shareholders has increased from 18,426 in June 2019 to 27,702 in March 2026.
- +Promoter holding of 53.6507% as of March 2026 indicates continued significant insider ownership.
Negatives
- −The company has consistently reported negative net profits, with -14.7573 Cr in Mar 2025 and -21.7306 Cr in Mar 2024.
- −The profit margin is significantly negative at -135.56%, indicating substantial losses.
- −Return on equity (ROE) is -26.3% and return on capital employed (ROCE) is -22.2064%, reflecting poor capital efficiency.
- −Promoters have pledged 20.66% of their shareholding as of March 2026.
- −Annual revenue has declined from Rs 202.4371 Cr in Mar 2021 to Rs 104.4343 Cr in Mar 2024, before increasing to Rs 147.4603 Cr in Mar 2025.
Financial Performance
Lasa Supergenerics Ltd. reported a revenue of Rs 147.46 Cr for the financial year ending March 2025. This follows a trend of fluctuating revenues, with Rs 202.4371 Cr in Mar 2021, Rs 137.4014 Cr in Mar 2022, Rs 131.3724 Cr in Mar 2023, and Rs 104.4343 Cr in Mar 2024. The net profit has been consistently negative, reported at -14.7573 Cr in Mar 2025, compared to -21.7306 Cr in Mar 2024 and -38.6207 Cr in Mar 2023.
Profitability & Returns
The company's profitability metrics indicate challenges. The profit margin for the latest period is -135.56%. Return on equity (ROE) stands at -26.3%, and return on capital employed (ROCE) is -22.2064%. Earnings per share (EPS) for March 2025 was -2.95, following annual EPS figures of -4.34 in Mar 2024 and -7.71 in Mar 2023, and a positive EPS of 5.6 in Mar 2021.
Balance Sheet
Lasa Supergenerics Ltd. has a debt-to-equity ratio of 0.13. The book value per share is Rs 9.9. No dividend yield was reported. The company's financial structure shows a reliance on debt, though the proportion to equity is relatively low.
Ownership & Pledges
As of March 31, 2026, promoter shareholding in Lasa Supergenerics Ltd. was 53.6507%, with public shareholding at 46.3493%. No FII or DII holding was reported. Promoters have pledged 20.66% of their shareholding. The number of shareholders has increased to 27,702 from 18,426 in June 2019.
Quarterly Performance
Quarterly results show negative net profit in recent periods. For Mar 2026, the company reported a revenue of -0.13 Cr and a net profit of -4.16 Cr. This is after a net profit of -2.55 Cr on a revenue of 2.2 Cr in Dec 2025. The highest quarterly revenue in recent periods was 39.14 Cr in Mar 2025, with a net profit of -14.29 Cr.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.